PATENT CLAIM ANALYSIS

Application Number: 15967484
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-09
Patent Classification: ["424", "133100"]

Abstract:
The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

Claim (Index 13):
The method of  claim 1 , wherein the first bacteria are selected from (i)  Staphylococcus aureus  that is resistant to an antibiotic selected from methicillin, vancomycin, linezolid, daptomycin, quinupristin, dalfopristin and teicoplanin; (ii)  Pseudomonas aeuroginosa  that is resistant to an antibiotic selected from cephalosporins, carbapenems, fluoroquinolones, aminoglycosides and colistin; (iii)  Klebsiella  species that is resistant to carbapenem; (iv)  Streptoccocus  species that is resistant to an antibiotic selected from erythromycin, clindamycin, beta-lactam, macrolide, amoxicillin, azithromycin and penicillin; (v)  Salmonella  species that is resistant to an antibiotic selected from ceftriaxone, azithromycin and ciprofloxacin; (vi)  Shigella  species that is resistant to ciprofloxacin or azithromycin; (vii)  Mycobacterium tuberculosis  that is resistant to an antibiotic selected from Resistance to isoniazid (INH), rifampicin (RMP), fluoroquinolone, amikacin, kanamycin, capreomycin and azithromycin; (viii)  Enterococcus  species that is resistant to vancomycin; (ix) Enterobacteriaceae species that is resistant to an antibiotic selected from cephalosporin and carbapenem; (x)  E coli  that is resistant to an antibiotic selected from trimethoprim, itrofurantoin, cefalexin and amoxicillin; (xi)  Clostridium  species that is resistant to metronidazole (MTZ), fluoroquinolone or carbapenem; (xii)  Neisseria gonnorrhoea  that is resistant to an antibiotic selected from cefixime, ceftriaxone, azithromycin and tetracycline; (xiii)  Acinetoebacter baumannii  that is resistant to an antibiotic selected from beta-lactam, meropenem and carbapenem; and (xiv)  Campylobacter  species that is resistant to ciprofloxacin or azithromycin.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 91.0
- Lexical Diversity: 1.87179
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15460962', '15160405', '15817135', '15817139', '15817142']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7394358243615778
- 35 USC 102 Novelty (BERT): 0.5120309359387373
- Combined Prediction Score: 0.7166953355192939
- Mean Citation Score: 286.884746
- Max Citation Score: 305.17386
- Similarity Product: 226.1292454169333

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test